Web sites advocate pill-splitting to cut drug costs

1 August 2001

Pharmaceutical companies have reacted with alarm to advice being givenon Internet web sites, including DestinationRx.com and Rxaminer.com, that patients and doctors should consider cutting pills in half to save on drug costs, according to a report in the Wall Street Journal. The advice takes advantage of pharmaceutical company practice to use the same price for a range of different strengths of a product, so that the cost is not a factor when doctors make dosing decisions.

Giving an example, the WSJ notes that Pfizer's Viagra costs $8.20 for a 50mg pill, the same as for 100mg, so patients requiring the lower dose can halve the cost of each treatment. The pharmaceutical industry contends, however, that the practice sets a dangerous precedent, as certain medications - such as capsules or extended-release formulations - cannot be cut in half without the risk of compromising their efficacy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight